EA201591205A1 - Способ получения противоопухолевого агента 6-(7-((1-аминоциклопропил)-метокси)-6-метоксихинолин-4-илокси)-n-метил-1-нафтамида и его кристаллической структуры - Google Patents

Способ получения противоопухолевого агента 6-(7-((1-аминоциклопропил)-метокси)-6-метоксихинолин-4-илокси)-n-метил-1-нафтамида и его кристаллической структуры

Info

Publication number
EA201591205A1
EA201591205A1 EA201591205A EA201591205A EA201591205A1 EA 201591205 A1 EA201591205 A1 EA 201591205A1 EA 201591205 A EA201591205 A EA 201591205A EA 201591205 A EA201591205 A EA 201591205A EA 201591205 A1 EA201591205 A1 EA 201591205A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methyl
aminocyclopropyl
nafthamide
methoxychinolin
iloxi
Prior art date
Application number
EA201591205A
Other languages
English (en)
Inventor
Гоцин Пол Чэн
Original Assignee
Адвенчен Фармасьютикалс, Ллс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Адвенчен Фармасьютикалс, Ллс filed Critical Адвенчен Фармасьютикалс, Ллс
Publication of EA201591205A1 publication Critical patent/EA201591205A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/06—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/24—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/26—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C07C309/66—Methanesulfonates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Quinoline Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Изобретение относится к новому способу синтеза 6-(7-((1-аминоциклопропил)метокси)-6-метоксихинолин-4-илокси)-N-метил-1-нафтамида (AL3810) путем удаления защитной группы замещенного бензил-1-((6-метокси-4-(5-(метилкарбамоил)нафталин-2-илокси)хинолин-7-илокси)метил)циклопропилкарбамата (формула I) в разбавленной или слабокислой среде. Также была получена стабильная кристаллическая форма 6-(7-((1-аминоциклопропил)метокси)-6-метоксихинолин-4-илокси)-N-метил-1-нафтамида
EA201591205A 2013-01-18 2014-01-17 Способ получения противоопухолевого агента 6-(7-((1-аминоциклопропил)-метокси)-6-метоксихинолин-4-илокси)-n-метил-1-нафтамида и его кристаллической структуры EA201591205A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361754516P 2013-01-18 2013-01-18
PCT/US2014/011948 WO2014113616A1 (en) 2013-01-18 2014-01-17 Process for preparing the anti-tumor agent 6-(7-((1-aminocyclopropyl) methoxy)-6-methoxyquinolin-4-yloxy)-n-methyl-1-naphthamide and its crystalline

Publications (1)

Publication Number Publication Date
EA201591205A1 true EA201591205A1 (ru) 2015-12-30

Family

ID=51210076

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591205A EA201591205A1 (ru) 2013-01-18 2014-01-17 Способ получения противоопухолевого агента 6-(7-((1-аминоциклопропил)-метокси)-6-метоксихинолин-4-илокси)-n-метил-1-нафтамида и его кристаллической структуры

Country Status (18)

Country Link
US (1) US9783498B2 (ru)
EP (1) EP2945931A4 (ru)
JP (1) JP2016506917A (ru)
KR (1) KR102275034B1 (ru)
CN (2) CN104936946A (ru)
AU (1) AU2014207482A1 (ru)
BR (1) BR112015017100A2 (ru)
CA (1) CA2896898A1 (ru)
EA (1) EA201591205A1 (ru)
HK (2) HK1213563A1 (ru)
IL (1) IL239877B (ru)
MA (1) MA38274A1 (ru)
MX (1) MX2015008543A (ru)
PH (1) PH12015501571A1 (ru)
RU (1) RU2015127211A (ru)
SG (1) SG11201505389WA (ru)
WO (1) WO2014113616A1 (ru)
ZA (1) ZA201505043B (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105311029A (zh) 2014-06-06 2016-02-10 正大天晴药业集团股份有限公司 抗肿瘤活性的喹啉衍生物
CN105311030B (zh) 2014-06-06 2020-03-24 正大天晴药业集团股份有限公司 用于抗肿瘤的螺取代化合物
AU2015290007B2 (en) 2014-07-14 2019-11-21 Advenchen Pharmaceuticals, Nanjing Ltd. Fused quinoline compunds as pi3k, mTor inhibitors
EP3231797B1 (en) 2014-12-09 2020-02-26 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Quinoline derivative against non-small cell lung cancer
US9751859B2 (en) * 2015-05-04 2017-09-05 Advenchen Pharmaceuticals, LLC Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine, its crystalline form and its salts
ES2782113T3 (es) 2015-07-11 2020-09-10 Advenchen Pharmaceuticals Llc Compuestos de quinolina fusionados como inhibidores de PI3K/mTor
CN107296811B (zh) 2016-04-15 2022-12-30 正大天晴药业集团股份有限公司 一种用于治疗胃癌的喹啉衍生物
CN115057815A (zh) 2018-03-02 2022-09-16 正大天晴药业集团股份有限公司 作为c-Met激酶抑制剂的化合物的结晶及其制备方法和用途
CN110483392A (zh) * 2018-05-14 2019-11-22 上海海和药物研究开发有限公司 合成n-保护的喹啉-7-基氧基甲基环丙基胺衍生物的方法及合成中间体
CN110483393A (zh) * 2018-05-14 2019-11-22 上海海和药物研究开发有限公司 德立替尼的晶型
CN115160221B (zh) * 2022-07-26 2024-10-18 恩祺生物科技(上海)有限公司 德立替尼晶型化合物和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8163923B2 (en) * 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
US8148532B2 (en) * 2007-03-14 2012-04-03 Guoqing Paul Chen Spiro substituted compounds as angiogenesis inhibitors
IT1393351B1 (it) * 2009-03-16 2012-04-20 Eos Ethical Oncology Science Spa In Forma Abbreviata Eos Spa Procedimento per la preparazione della 6-(7-((1-amminociclopropil)metossi)-6-metossichinolin-4-ilossi)-n-metil-1-naftammide e suoi intermedi di sintesi
US8664244B2 (en) * 2010-09-12 2014-03-04 Advenchen Pharmaceuticals, LLC Compounds as c-Met kinase inhibitors
WO2013081154A1 (ja) * 2011-12-02 2013-06-06 味の素株式会社 キナーゼ阻害剤の副作用低減剤
MX2015005839A (es) * 2012-11-08 2015-12-17 Clearside Biomedical Inc Metodos y dispositivos para el tratamiento de trastornos oculares en sujetos humanos.

Also Published As

Publication number Publication date
BR112015017100A2 (pt) 2017-07-11
CN104936946A (zh) 2015-09-23
KR20150108871A (ko) 2015-09-30
ZA201505043B (en) 2017-11-29
KR102275034B1 (ko) 2021-07-12
EP2945931A4 (en) 2016-10-12
IL239877A0 (en) 2015-08-31
MX2015008543A (es) 2015-11-16
AU2014207482A1 (en) 2015-08-13
RU2015127211A (ru) 2017-03-03
US9783498B2 (en) 2017-10-10
JP2016506917A (ja) 2016-03-07
SG11201505389WA (en) 2015-08-28
WO2014113616A1 (en) 2014-07-24
IL239877B (en) 2018-07-31
CN111454206A (zh) 2020-07-28
HK1213563A1 (zh) 2016-07-08
US20150353496A1 (en) 2015-12-10
HK1217328A1 (zh) 2017-01-06
MA38274A1 (fr) 2017-02-28
PH12015501571A1 (en) 2015-10-05
CA2896898A1 (en) 2014-07-24
EP2945931A1 (en) 2015-11-25

Similar Documents

Publication Publication Date Title
EA201591205A1 (ru) Способ получения противоопухолевого агента 6-(7-((1-аминоциклопропил)-метокси)-6-метоксихинолин-4-илокси)-n-метил-1-нафтамида и его кристаллической структуры
EA201591527A1 (ru) Новые производные пиридина
BR112014012378A2 (pt) identificação de condições de localização assistida pelo usuário
DK3489226T3 (da) Hæmmere for natriumglucose-cotransporter 1
DK2768796T3 (da) Fremgangsmåde til fremstilling af quinolin-derivater
EA201591064A1 (ru) Новые производные пиридина
BR112013030830A2 (pt) processo de preparação de composto da fórmula (i) e estetrol obtido diretamente por meio do processo
EA201591567A1 (ru) Новые производные пиридина
NZ719568A (en) Crystals of diazabicyclooctane derivative and production method for crystals of diazabicyclooctane derivative
CY1118079T1 (el) Μεθοδος παρασκευης του αλατος l-αργινινικης περινδοπριλης
IL267196B (en) Benzo-fused heterocyclic compounds used as gpr120 agonists
CY1121116T1 (el) Νεα μεθοδος για την συνθεση αγομελατινης
EP2948437A4 (en) NEW APPROACH FOR THE SYNTHESIS OF CATÉCHINES
EA201600002A1 (ru) Производные пролекарства замещенных триазолопиридинов
ITRM20120277A1 (it) Procedimento per ridurre la larghezza di incrinature.
IN2013MU04056A (ru)
MX371011B (es) Intermediarios y métodos para sintetizar derivados de calicheamicina.
WO2014167509A3 (en) Loxoprofen polymorphs and process for preparation of the same
FR3010407B1 (fr) Procede de preparation de derives oxysulfures et fluores par sulfination
MX2015015346A (es) Procedimiento para la preparacion de intermediarios de acido boronico.
WO2015001565A3 (en) "an improved process for the preparation of 3-aryloxy-3- phenylpropylamine and salt thereof"
EA201690229A1 (ru) Способ получения дронедарона и его солей
CY1120160T1 (el) Νεα μεθοδος για την συνθεση 7-μεθοξυ-ναφθαλινο-1-καρβαλδεϋδης και εφαρμογη αυτης στην συνθεση της αγομελατινης
RU2022132278A (ru) Производное хинолина высокой чистоты и способ его получения
EA201690934A1 (ru) Способ получения олопатадина и его силильных производных